Mitochondria death/survival signaling pathways in cardiotoxicity induced by anthracyclines and anticancer-targeted therapies

Biochemistry Research International

Volumn , Issue , 2012, Pages

  Montaigne, David ^a   Hurt, Christopher ^a   Neviere, Remi ^a  

^a UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84859724714     PISSN: 20902247     EISSN: 20902255     Source Type: Journal    
DOI: 10.1155/2012/951539     Document Type: Review

References (106)

1. Eschenhagen T., Force T., Ewer M. S., De Keulenaer G. W., Suter T. M., Anker S. D., Avkiran M., De Azambuja E., Balligand J. L., Brutsaert D. L., Condorelli G., Hansen A., Heymans S., Hill J. A., Hirsch E., Hilfiker-Kleiner D., Janssens S., De Jong S., Neubauer G., Pieske B., Ponikowski P., Pirmohamed M., Rauchhaus M., Sawyer D., Sugden P. H., Wojta J., Zannad F., Shah A. M., Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology European Journal of Heart Failure 2011 13 1 1 10
2. Ewer M. S., Ewer S. M., Cardiotoxicity of anticancer treatments: what the cardiologist needs to know Nature Reviews Cardiology 2010 7 10 564 575
3. van Dalen E. C., Caron H. N., Dickinson H. O., Kremer L. C., Cardioprotective interventions for cancer patients receiving anthracyclines Cochrane Database of Systematic Reviews 2005 1
4. Ferreira A. L. A., Matsubara L. S., Matsubara B. B., Anthracycline- induced cardiotoxicity Cardiovascular and Hematological Agents in Medicinal Chemistry 2008 6 4 278 281
5. Monsuez J. J., Charniot J. C., Vignat N., Artigou J. Y., Cardiac side-effects of cancer chemotherapy International Journal of Cardiology 2010 144 1 3 15
6. Saif M. W., Shah M. M., Shah A. R., Fluoropyrimidine-associated cardiotoxicity: revisited Expert Opinion on Drug Safety 2009 8 2 191 202
7. Gressett S. M., Shah S. R., Intricacies of bevacizumab-induced toxicities and their management Annals of Pharmacotherapy 2009 43 3 490 501
8. Meinardi M. T., Van Der Graaf W. T. A., Van Veldhuisen D. J., Gietema J. A., De Vries E. G. E., Sleijfer D. T., Detection of anthracycline-induced cardiotoxicity Cancer Treatment Reviews 1999 25 4 237 247 (Pubitemid 29417681)
9. Buzdar A. U., Marcus C., Smith T. L., Blumenschein G. R., Early and delayed clinical cardiotoxicity of doxorubicin Cancer 1985 55 12 2761 2765 (Pubitemid 15008311)
10. Yeh E. T., Bickford C. L., Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management Journal of the American College of Cardiology 2009 53 24 2231 2247
11. Aggarwal S., Targeted cancer therapies Nature Reviews Drug Discovery 2010 9 6 427 428
12. Force T., Kolaja K. L., Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes Nature Reviews Drug Discovery 2011 10 2 111 126
13. Force T., Krause D. S., Van Etten R. A., Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition Nature Reviews Cancer 2007 7 5 332 344 (Pubitemid 46652481)
14. Cheng H., Force T., Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics Circulation Research 2010 106 1 21 34
15. Chen M. H., Kerkel R., Force T., Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics Circulation 2008 118 1 84 95
16. Crone S. A., Zhao Y. Y., Fan L., Gu Y., Minamisawa S., Liu Y., Peterson K. L., Chen J., Kahn R., Condorelli G., Ross J., Chien K. R., Lee K. F., ErbB2 is essential in the prevention of dilated cardiomyopathy Nature Medicine 2002 8 5 459 465 (Pubitemid 34546747)
17. De Keulenaer G. W., Doggen K., Lemmens K., The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy Circulation Research 2010 106 1 35 46
18. Sawyer D. B., Peng X., Chen B., Pentassuglia L., Lim C. C., Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Progress in Cardiovascular Diseases 2010 53 2 105 113
19. Chen M. H., Colan S. D., Diller L., Cardiovascular disease: cause of morbidity and mortality in adult survivors of childhood cancers Circulation Research 2011 108 5 619 628
20. Zhang Y. W., Shi J., Li Y. J., Wei L., Cardiomyocyte death in doxorubicin-induced cardiotoxicity Archivum Immunologiae et Therapiae Experimentalis 2009 57 6 435 445
21. Ryberg M., Nielsen D., Cortese G., Nielsen G., Skovsgaard T., Andersen P. K., New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients Journal of the National Cancer Institute 2008 100 15 1058 1067
22. Bernaba B. N., Chan J. B., Lai C. K., Fishbein M. C., Pathology of late-onset anthracycline cardiomyopathy Cardiovascular Pathology 2010 19 5 308 311
23. De Graaf H., Dolsma W. V., Willemse P. H. B., Van Der Graaf W. T. A., Sleijfer D. T., De Vries E. G. E., Mulder N. H., Cardiotoxicity from intensive chemotherapy combined with radiotherapy in breast cancer British Journal of Cancer 1997 76 7 943 945 (Pubitemid 27401949)
24. Aleman B. M. P., Van Den Belt-Dusebout A. W., De Bruin M. L., Van 't Veer M. B., Baaijens M. H. A., De Boer J. P., Hart A. A. M., Klokman W. J., Kuenen M. A., Ouwens G. M., Bartelink H., Van Leeuwen F. E., Late cardiotoxicity after treatment for Hodgkin lymphoma Blood 2007 109 5 1878 1886 (Pubitemid 46348183)
25. Ganz P. A., Hussey M. A., Moinpour C. M., Unger J. M., Hutchins L. F., Dakhil S. R., Giguere J. K., Goodwin J. W., Martino S., Albain K. S., Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol S8897 Journal of Clinical Oncology 2008 26 8 1223 1230
26. Swain S. M., Whaley F. S., Ewer M. S., Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials Cancer 2003 97 11 2869 2879 (Pubitemid 36605157)
27. imnek T., trba M., Popelov O., Adamcov M., Hrdina R., Geri V., Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron Pharmacological Reports 2009 61 1 154 171
28. Raschi E., Vasina V., Ursino M. G., Boriani G., Martoni A., de Ponti F., Anticancer drugs and cardiotoxicity: insights and perspectives in the era of targeted therapy Pharmacology and Therapeutics 2010 125 2 196 218
29. Tokarska-Schlattner M., Zaugg M., Zuppinger C., Wallimann T., Schlattner U., New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics Journal of Molecular and Cellular Cardiology 2006 41 3 389 405 (Pubitemid 44362995)
30. Chen B., Peng X., Pentassuglia L., Lim C. C., Sawyer D. B., Molecular and cellular mechanisms of anthracycline cardiotoxicity Cardiovascular Toxicology 2007 7 2 114 121 (Pubitemid 47339857)
31. Sardo V. A., Oliveira P. J., Holy J., Oliveira C. R., Wallace K. B., Morphological alterations induced by doxorubicin on H9c2 myoblasts: nuclear, mitochondrial, and cytoskeletal targets Cell Biology and Toxicology 2009 25 3 227 243
32. Rayson D., Richel D., Chia S., Jackisch C., van der Vegt S., Suter T., Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies Annals of Oncology 2008 19 9 1530 1539
33. Horie T., Ono K., Nishi H., Nagao K., Kinoshita M., Watanabe S., Kuwabara Y., Nakashima Y., Takanabe-Mori R., Nishi E., Hasegawa K., Kita T., Kimura T., Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway Cardiovascular Research 2010 87 4 656 664
34. Keizer H. G., Pinedo H. M., Schuurhuis G. J., Joenje H., Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity Pharmacology and Therapeutics 1990 47 2 219 231 (Pubitemid 20228581)
35. Wojnowski L., Kulle B., Schirmer M., Schlter G., Schmidt A., Rosenberger A., Vonhof S., Bickebller H., Toliat M. R., Suk E. K., Tzvetkov M., Kruger A., Seifert S., Kloess M., Hahn H., Loeffler M., Nrnberg P., Pfreundschuh M., Trmper L., Brockmller J., Hasenfuss G., NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity Circulation 2005 112 24 3754 3762 (Pubitemid 43739516)
36. Minotti G., Ronchi R., Salvatorelli E., Menna P., Cairo G., Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy Cancer Research 2001 61 23 8422 8428 (Pubitemid 33131119)
37. Fogli S., Nieri P., Breschi M. C., The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage The FASEB Journal 2004 18 6 664 675 (Pubitemid 38451788)
38. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L., Anthracyclines: molecular advances and pharmacologie developments in antitumor activity and cardiotoxicity Pharmacological Reviews 2004 56 2 185 229 (Pubitemid 38720829)
39. Rowan R. A., Masek M. A., Billingham M. E., Ultrastructural morphometric analysis of endomyocardial biopsies. Idiopathic dilated cardiomyopathy, anthracycline cardiotoxicity, and normal myocardium American Journal of Cardiovascular Pathology 1988 2 2 137 144
40. Berthiaume J. M., Wallace K. B., Adriamycin-induced oxidative mitochondrial cardiotoxicity Cell Biology and Toxicology 2007 23 1 15 25 (Pubitemid 44950185)
41. Wallace K. B., Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis Cardiovascular Toxicology 2007 7 2 101 107 (Pubitemid 47339855)
42. Bernardi P., Krauskopf A., Basso E., Petronilli V., Blalchy-Dyson E., Di Lisa F., Forte M. A., The mitochondrial permeability transition from in vitro artifact to disease target FEBS Journal 2006 273 10 2077 2099
43. Halestrap A. P., What is the mitochondrial permeability transition pore? Journal of Molecular and Cellular Cardiology 2009 46 6 821 831
44. Baines C. P., The mitochondrial permeability transition pore and ischemia-reperfusion injury Basic Research in Cardiology 2009 104 2 181 188
45. Baines C. P., The molecular composition of the mitochondrial permeability transition pore Journal of Molecular and Cellular Cardiology 2009 46 6 850 857
46. Nakagawa T., Shimizu S., Watanabe T., Yamaguchi O., Otsu K., Yamagata H., Inohara H., Kubo T., Tsujimoto Y., Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death Nature 2005 434 7033 652 658 (Pubitemid 40488558)
47. Schinzel A. C., Takeuchi O., Huang Z., Fisher J. K., Zhou Z., Rubens J., Hetz C., Danial N. N., Moskowitz M. A., Korsmeyer S. J., Cyclophilin D is a component of mitochondrial permeability transition and mediates neuronal cell death after focal cerebral ischemia Proceedings of the National Academy of Sciences of the United States of America 2005 102 34 12005 12010 (Pubitemid 41291119)
48. Nakayama H., Chen X., Baines C. P., Klevitsky R., Zhang X., Zhang H., Jaleel N., Chua B. H. L., Hewett T. E., Robbins J., Houser S. R., Molkentin J. D., Ca 2+ - and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure The Journal of Clinical Investigation 2007 117 9 2431 2444 (Pubitemid 47494345)
49. Arbustini E., Brega A., Narula J., Ultrastructural definition of apoptosis in heart failure Heart Failure Reviews 2008 13 2 121 135
50. L'Ecuyer T., Allebban Z., Thomas R., Vander Heide R., Glutathione S-transferase overexpression protects against anthracycline-induced H9C2 cell death American Journal of Physiology 2004 286 6 H2057 H2064 (Pubitemid 38685217)
51. Lu L., Wu W., Yan J., Li X., Yu H., Yu X., Adriamycin-induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure International Journal of Cardiology 2009 134 1 82 90
52. Nicolay K., Fok J. J., Voorhout W., Cytofluorescence detection of adriamycin-mitochondria interactions in isolated, perfused rat heart Biochimica et Biophysica Acta 1986 887 1 35 41 (Pubitemid 16089098)
53. Tokarska-Schlattner M., Zaugg M., Da Silva R., Lucchinetti E., Schaub M. C., Wallimann T., Schlattner U., Acute toxicity of doxorubicin on isolated perfused heart: response of kinases regulating energy supply American Journal of Physiology 2005 289 1 H37 H47 (Pubitemid 40934080)
54. Javadov S., Hunter J. C., Barreto-Torres G., Parodi-Rullan R., Targeting the mitochondrial permeability transition: cardiac ischemia-reperfusion versus carcinogenesis Cellular Physiology and Biochemistry 2011 27 3-4 179 190
55. Solem L. E., Wallace K. B., Selective activation of the sodium-independent, cyclosporin A-sensitive calcium pore of cardiac mitochondria by doxorubicin Toxicology and Applied Pharmacology 1993 121 1 50 57 (Pubitemid 23221273)
56. Solem L. E., Henry T. R., Wallace K. B., Disruption of mitochondrial calcium homeostasis following chronic doxorubicin administration Toxicology and Applied Pharmacology 1994 129 2 214 222 (Pubitemid 24380792)
57. Solem L. E., Heller L. J., Wallace K. B., Wallace K. B., Dose-dependent increase in sensitivity to calcium-induced mitochondrial dysfunction and cardiomyocyte cell injury by doxorubicin Journal of Molecular and Cellular Cardiology 1996 28 5 1023 1032 (Pubitemid 26169308)
58. Zhou S., Starkov A., Froberg M. K., Leino R. L., Wallace K. B., Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin Cancer Research 2001 61 2 771 777 (Pubitemid 32128645)
59. Al-Nasser I. A., In vivo prevention of adriamycin cardiotoxicity by cyclosporin A or FK506 Toxicology 1998 131 2-3 175 181 (Pubitemid 28544947)
60. Marechal X., Montaigne D., Marciniak C., Marchetti P., Hassoun S. M., Beauvillain J. C., Lancel S., Neviere R., Doxorubicin-induced cardiac dysfunction is attenuated by ciclosporin treatment in mice through improvements in mitochondrial bioenergetics Clinical Science 2011 121 9 405 413
61. Montaigne D., Marechal X., Preau S., Baccouch R., Modine T., Fayad G., Lancel S., Neviere R., Doxorubicin induces mitochondrial permeability transition and contractile dysfunction in the human myocardium Mitochondrion 2011 11 1 22 26
62. Ovize M., Baxter G. F., Di Lisa F., Ferdinandy P., Garcia-Dorado D., Hausenloy D. J., Heusch G., Vinten-Johansen J., Yellon D. M., Schulz R., Postconditioning and protection from reperfusion injury: where do we stand: position Paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology Cardiovascular Research 2010 87 3 406 423
63. Kim K. H., Oudit G. Y., Backx P. H., Erythropoietin protects against doxorubicin-induced cardiomyopathy via a phosphatidylinositol 3-kinase-dependent pathway Journal of Pharmacology and Experimental Therapeutics 2008 324 1 160 169 (Pubitemid 350294149)
64. Suliman H. B., Carraway M. S., Ali A. S., Reynolds C. M., Welty-Wolf K. E., Piantadosi C. A., The CO/HO system reverses inhibition of mitochondrial biogenesis and prevents murine doxorubicin cardiomyopathy The Journal of Clinical Investigation 2007 117 12 3730 3741 (Pubitemid 350224084)
65. Li K., Sung R. Y. T., Wei Z. H., Yang M., Nga H. P., Shuk M. L., Wood Y. C., Zhao H., Man Y. T., Tai F. F., Chi K. L., Yuek O. W., Pak C. N., Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin Circulation 2006 113 18 2211 2220
66. Fan G. C., Zhou X., Wang X., Song G., Qian J., Nicolaou P., Chen G., Ren X., Kranias E. G., Heat shock protein 20 interacting with phosphorylated akt reduces doxorubicin-triggered oxidative stress and cardiotoxicity Circulation Research 2008 103 11 1270 1279
67. Thandavarayan R. A., Watanabe K., Sari F. R., Ma M., Lakshmanan A. P., Giridharan V. V., Gurusamy N., Nishida H., Konishi T., Zhang S., Muslin A. J., Kodama M., Aizawa Y., Modulation of doxorubicin-induced cardiac dysfunction in dominant-negative p38 mitogen-activated protein kinase mice Free Radical Biology and Medicine 2010 49 9 1422 1431
68. Khan M., Varadharaj S., Ganesan L. P., Shobha J. C., Naidu M. U., Parinandi N. L., Tridandapani S., Kutala V. K., Kuppusamy P., C-phycocyanin protects against ischemia-reperfusion injury of heart through involvement of p38 MAPK and ERK signaling American Journal of Physiology 2006 290 5 H2136 H2145
69. Bartha E., Solti I., Szabo A., Olah G., Magyar K., Szabados E., Kalai T., Hideg K., Toth K., Gero D., Szabo C., Sumegi B., Halmosi R., Regulation of kinase cascade activation and heat shock protein expression by poly(ADP-ribose) polymerase inhibition in doxorubicin-induced heart failure Journal of Cardiovascular Pharmacology 2011 58 4 380 391
70. Berthiaume J. M., Wallace K. B., Persistent alterations to the gene expression profile of the heart subsequent to chronic doxorubicin treatment Cardiovascular Toxicology 2007 7 3 178 191 (Pubitemid 47575003)
71. Pointon A. V., Walker T. M., Phillips K. M., Luo J., Riley J., Zhang S. D., Parry J. D., Lyon J. J., Marczylo E. L., Gant T. W., Doxorubicin in vivo rapidly alters expression and translation of myocardial electron transport chain genes, leads to ATP loss and caspase 3 activation PloS One 2010 5 9
72. Abdel-Aleem S., El-Merzabani M. M., Sayed-Ahmed M., Taylor D. A., Lowe J. E., Acute and chronic effects of adriamycin on fatty acid oxidation in isolated cardiac myocytes Journal of Molecular and Cellular Cardiology 1997 29 2 789 797 (Pubitemid 27192884)
73. Wakasugi S., Fischman A. J., Babich J. W., Callahan R. J., Elmaleh D. R., Wilkinson R., Strauss H. W., Myocardial substrate utilization and left ventricular function in adriamycin cardiomyopathy Journal of Nuclear Medicine 1993 34 9 1529 1535 (Pubitemid 23254351)
74. Hrelia S., Fiorentini D., Maraldi T., Angeloni C., Bordoni A., Biagi P. L., Hakim G., Doxorubicin induces early lipid peroxidation associated with changes in glucose transport in cultured cardiomyocytes Biochimica et Biophysica Acta 2002 1567 150 156 (Pubitemid 35454056)
75. Jeyaseelan R., Poizat C., Wu H. Y., Kedes L., Molecular mechanisms of doxorubicin-induced cardiomyopathy. Selective suppression of Reiske iron-sulfur protein, ADP/ATP translocase, and phosphofructokinase genes is associated with ATP depletion in rat cardiomyocytes The Journal of Biological Chemistry 1997 272 9 5828 5832 (Pubitemid 27102415)
76. Thompson K. L., Rosenzweig B. A., Zhang J., Knapton A. D., Honchel R., Lipshultz S. E., Retief J., Sistare F. D., Herman E. H., Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in rats Cancer Chemotherapy and Pharmacology 2010 66 2 303 314
77. Fernandez-Marcos P. J., Auwerx J., Regulation of PGC-1, a nodal regulator of mitochondrial biogenesis American Journal of Clinical Nutrition 2011 93 4 884S 890S
78. trba M., Popelov O., Leno J., Fukov A., Brkov E., Mazurov Y., Jirkovsk E., imnek T., Adamcov M., Miuda S., Stulk J., Gerl V., Proteomic insights into chronic anthracycline cardiotoxicity Journal of Molecular and Cellular Cardiology 2011 50 5 849 862
79. Kumar S. N., Konorev E. A., Aggarwal D., Kalyanaraman B., Analysis of proteome changes in doxorubicin-treated adult rat cardiomyocyte Journal of Proteomics 2011 74 5 683 697
80. Jones R. L., Miles D. W., Use of endomyocardial biopsy to assess anthracycline-induced cardiotoxicity Lancet Oncology 2005 6 2 67 (Pubitemid 40197687)
81. Mackay B., Ewer M. S., Carrasco C. H., Benjamin R. S., Assessment of anthracycline cardiomyopathy by endomyocardial biopsy Ultrastructural Pathology 1994 18 1-2 203 211 (Pubitemid 24131629)
82. Lim C. C., Zuppinger C., Guo X., Kuster G. M., Helmes M., Eppenberger H. M., Suter T. M., Liao R., Sawyer D. B., Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes The Journal of Biological Chemistry 2004 279 9 8290 8299 (Pubitemid 38294721)
83. Arai M., Yoguchi A., Takizawa T., Yokoyama T., Kanda T., Kurabayashi M., Nagai R., Mechanism of doxorubicin-induced inhibition of sarcoplasmic reticulum Ca 2+ -ATPase gene transcription Circulation Research 2000 86 1 8 14 (Pubitemid 30044162)
84. Holmberg S. R. M., Williams A. J., Patterns of interaction between anthraquinone drugs and the calcium-release channel from cardiac sarcoplasmic reticulum Circulation Research 1990 67 2 272 283 (Pubitemid 20242568)
85. Wang Y. X., Korth M., Effects of doxorubicin on excitation-contraction coupling in guinea pig ventricular myocardium Circulation Research 1995 76 4 645 653
86. Olson R. D., Mushlin P. S., Brenner D. E., Fleischer S., Cusack B. J., Chang B. K., Boucek R. J., Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol Proceedings of the National Academy of Sciences of the United States of America 1988 85 10 3585 3589
87. Kim Y., Ma A. G., Kitta K., Fitch S. N., Ikeda T., Ihara Y., Simon A. R., Evans T., Suzuki Y. J., Anthracycline-induced suppression of GATA-4 transcription factor: implication in the regulation of cardiac myocyte apoptosis Molecular Pharmacology 2003 63 2 368 377 (Pubitemid 36158372)
88. Aries A., Paradis P., Lefebvre C., Schwartz R. J., Nemer M., Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity Proceedings of the National Academy of Sciences of the United States of America 2004 101 18 6975 6980 (Pubitemid 38596428)
89. Kobayashi S., Volden P., Timm D., Mao K., Xu X., Liang Q., Transcription factor GATA4 inhibits doxorubicin-induced autophagy and cardiomyocyte death The Journal of Biological Chemistry 2010 285 1 793 804
90. Pikkarainen S., Tokola H., Kerkel R., Ruskoaho H., GATA transcription factors in the developing and adult heart Cardiovascular Research 2004 63 2 196 207 (Pubitemid 38900834)
91. Li L., Takemura G., Li Y., Miyata S., Esaki M., Okada H., Kanamori H., Ngin C. K., Maruyama R., Ogino A., Minatoguchi S., Fujiwara T., Fujiwara H., Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy Circulation 2006 113 4 535 543
92. Jeyaseelan R., Poizat C., Baker R. K., Abdishoo S., Isterabadi L. B., Lyons G. E., Kedes L., A novel cardiac-restricted target for doxorubicin. CARP, a nuclear modulator of gene expression in cardiac progenitor cells and cardiomyocytes The Journal of Biological Chemistry 1997 272 36 22800 22808 (Pubitemid 27386100)
93. Arimura T., Bos J. M., Sato A., Kubo T., Okamoto H., Nishi H., Harada H., Koga Y., Moulik M., Doi Y. L., Towbin J. A., Ackerman M. J., Kimura A., Cardiac ankyrin repeat protein gene (ANKRD1) mutations in hypertrophic cardiomyopathy Journal of the American College of Cardiology 2009 54 4 334 342
94. Poizat C., Puri P. L., Bai Y., Kedes L., Phosphorylation-dependent degradation of p300 by doxorubicin-activated p38 mitogen-activated protein kinase in cardiac cells Molecular and Cellular Biology 2005 25 7 2673 2687 (Pubitemid 40381631)
95. L'Ecuyer T., Sanjeev S., Thomas R., Novak R., Das L., Campbell W., Vander Heide R., DNA damage is an early event in doxorubicin-induced cardiac myocyte death American Journal of Physiology 2006 291 3 H1273 H1280 (Pubitemid 44343672)
96. Zhu W., Soonpaa M. H., Chen H., Shen W., Payne R. M., Liechty E. A., Caldwell R. L., Shou W., Field L. J., Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway Circulation 2009 119 1 99 106
97. Lemmens K., Doggen K., De Keulenaer G. W., Role of neuregulin-1/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure Circulation 2007 116 8 954 960 (Pubitemid 47300920)
98. Gum A., Martnez-Redondo V., Lpez-Soldado I., Cant C., Zorzano A., Emerging role of neuregulin as a modulator of muscle metabolism American Journal of Physiology 2010 298 4 E742 E750
99. Peng X., Chen B., Lim C. C., Sawyer D. B., The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine Molecular Interventions 2005 5 3 163 171 (Pubitemid 41018273)
100. Cheng H., Force T., Why do kinase inhibitors cause cardiotoxicity and what can be done about it? Progress in Cardiovascular Diseases 2010 53 2 114 120
101. Chu T. F., Rupnick M. A., Kerkela R., Dallabrida S. M., Zurakowski D., Nguyen L., Woulfe K., Pravda E., Cassiola F., Desai J., George S., Morgan J. A., Harris D. M., Ismail N. S., Chen J. H., Schoen F. J., Van den Abbeele A. D., Demetri G. D., Force T., Chen M. H., Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib The Lancet 2007 370 9604 2011 2019 (Pubitemid 350236338)
102. Kerkela R., Woulfe K. C., Durand J. B., Vagnozzi R., Kramer D., Chu T. F., Beahm C., Chen M. H., Force T., Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase Clinical and Translational Science 2009 2 1 15 25
103. Chen M.-B., Wu X.-Y., Gu J.-H., Guo Q.-T., Shen W.-X., Lu P.-H., Activation of AMP-activated protein kinase contributes to doxorubicin-induced cell death and apoptosis in cultured myocardial H9c2 cells Cell Biochemistry and Biophysics 2011 60 3 311 322
104. Kerkel R., Grazette L., Yacobi R., Iliescu C., Patten R., Beahm C., Walters B., Shevtsov S., Pesant S., Clubb F. J., Rosenzweig A., Salomon R. N., Van Etten R. A., Alroy J., Durand J. B., Force T., Cardiotoxicity of the cancer therapeutic agent imatinib mesylate Nature Medicine 2006 12 8 908 916 (Pubitemid 44175142)
105. Fernndez A., Sanguino A., Peng Z., Ozturk E., Chen J., Crespo A., Wulf S., Shavrin A., Qin C., Ma J., Trent J., Lin Y., Han H. D., Mangala L. S., Bankson J. A., Gelovani J., Samarel A., Bornmann W., Sood A. K., Lopez-Berestein G., An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic The Journal of Clinical Investigation 2007 117 12 4044 4054 (Pubitemid 350224113)
106. Reeve J. L. V., Szegezdi E., Logue S. E., Chonghaile T. N., O'Brien T., Ritter T., Samali A., Distinct mechanisms of cardiomyocyte apoptosis induced by doxorubicin and hypoxia converge on mitochondria and are inhibited by Bcl-xL Journal of Cellular and Molecular Medicine 2007 11 3 509 520 (Pubitemid 47153461)